Group items tagged

Nearly 70 years ago the UK Government recognised the imbalance of power between commercial landlords and tenants and passed the Landlord and Tenant Act 1954 (the Act), giving most commercial tenants a right of security of tenure. What is security of tenure? The Act grants tenants of business premises (so this would include pharmacy tenants) the right when the fixed term of their lease has ended to remain in occupation of the premises and the right to apply for the grant of a new lease. The landlord can only object to the grant of the new lease of the premises to the tenant, and therefore regain possession of the property on certain grounds set out in the Act. The parties to a lease can contract outside the provisions of the Act and where this is the case, a tenant would not have security of tenure. Most landlords will insist on no security of tenure where a lease is granted for a short term. As pharmacy leases have tended to be granted for longer terms (usually between 10 and 15 years) pharmacy tenants often have security of tenure. The Act sets out strict procedures which need to be followed to both contract outside the provisions of security of tenure and also to exercise the security of tenure rights granted by the Act. Pharmacists should take legal advice before agreeing to a pharmacy lease being excluded from the Act, and also at the end of their lease term whether or not they have security of tenure. If the lease is contracted outside of the Act, advice should be sought on agreeing new lease terms, if the pharmacist wishes to remain, as there will be no right to do so beyond the end of the lease term. If the lease is protected by the security of tenure provisions of the Act, advice should still be sought, as the Act prescribes a formal notice procedure that both the landlord and tenant must adhere to, before a new lease can be granted.

Community Pharmacy England has published new guidance to help members to complete the 2022/23 Data Security and Protection Toolkit (DSPTK). The Toolkit is used to make a pharmacy's information governance (IG) declaration and the deadline is Friday (30 June). Community Pharmacy England collaborated with the NHS DSPTK team to keep the workload associated with Toolkit completion manageable whilst maintaining the appropriate data security protections. Key differences in this year's Toolkit include- improvements to the Toolkit's layout; improvements to the question wording and pharmacy-specific tips; and the Toolkit displays the answers submitted by the pharmacy in the previous submission for various questions, allowing pharmacy owners to simply confirm that the information remains accurate and adjust this if necessary. The NHS Parent Organisation Code (POC) headquarters (HQ) batch submission feature also continues to enable to allow pharmacy owners (that own three or more pharmacies) to complete a single submission for all their premises.

Community Pharmacy England (CPE) has reminded community pharmacy owners that the deadline to complete the 2023/24 Data Security and Protection Toolkit to make their information governance (IG) declaration is 30 June 2024. Sometimes referred to as the "NHS IG toolkit", the DSPT is a set of security requirements that companies are required to fulfill to supply goods and services to the health service to ensure the safety and protection of sensitive patient information. To help community pharmacy contractors complete the mandatory questions within the Toolkit, CPE on Monday (12 February) published new guidance, which also contains references to other useful materials. CPE is working with the NHS DSPTK team to keep the workload associated with Toolkit completion manageable whilst ensuring that appropriate data security protections are maintained. Pharmacy owners with three or more pharmacies can complete a single submission for all their premises through the NHS Parent Organisation Code (POC) headquarters (HQ) batch submission feature.

Britain will start to roll out Merck's molnupiravir Covid-19 antiviral pill through a drug trial later this month, Susan Hopkins, chief medical adviser at the UK Health Security Agency said on Sunday (November 7). Last week Britain became the first country in the world to approve the potentially game-changing Covid-19 antiviral pill, jointly developed by US-based Merck & Co Inc and Ridgeback Biotherapeutics. The government said in October it had secured 480,000 courses of the Merck drug, as well as 250,000 courses of an antiviral pill developed by Pfizer Inc. Asked about the molnupiravir approval, Hopkins told BBC television: "That is great news and it will start to be rolled out through a drug trial in the end of this month/the beginning of December." Hopkins said all the trials so far had been done with the unvaccinated, so this would help understand how it will work in the wider vaccinated population.

Aspen has committed not to charge more for its six generic cancer drugs for the next 10 years in the UK, according to the Competition and Markets Authority (CMA). The CMA also clarified that "although these commitments were offered while the UK was a part of the European Union" they remain "legally binding". It added: "The CMA has now assisted the NHS to secure binding undertakings from Aspen, under the law of England and Wales, which enshrine the UK elements of the commitments and are enforceable by UK courts, including in relation to the supply of these drugs in Northern Ireland and Scotland." This allows NHS to monitor and ensure compliance by Aspen following the UK's exit from the EU. In 2017, the European Commission began an investigation into Aspen over concerns that the company had engaged in excessive pricing for 6 off-patent cancer medicines.

Hundreds of children in England are set to benefit from a treatment for cystic fibrosis - Kaftrio, after the UK's Medicines and Healthcare products Regulatory Agency (MHRA) confirmed an extension to its licence. With the licence extension, more than 1,300 children in England with cystic fibrosis, aged six to 11, are newly eligible for this treatment, which improves lung function and improves overall quality of life of patients. Earlier, Kaftrio was only licensed for those aged 12 and above. British patients were the first in Europe to benefit from Kaftrio, when NHS England secured a landmark deal in June 2020. NHS chief executive Amanda Pritchard said: "Since NHS staff delivered one of the fastest rollouts of Kaftrio in the world just over a year ago, the lives of thousands of patients with cystic fibrosis have been transformed. "Innovative treatments like Kaftrio are life-changing for patients and their families, and that is why the NHS has done all it can since we secured the deal for Kaftrio to ensure patients benefit as soon as possible.

Kate Bingham, the former head of the UK's Covid-19 Vaccine Taskforce who secured millions of doses for the country, said scientists should know within a week whether existing shots are effective against the Omicron variant of the coronavirus. Bingham, a venture capitalist who backed multiple vaccines at the start of the pandemic to secure early access for Britain, said she currently expected that the leading shots would still show efficacy. "The question is do they have the same level of efficacy?" she said on Wednesday. Bingham, who has returned to her role as managing partner at SV Health Investors, said Britain had built up the capability to quickly test existing vaccines against new variants. "It's not something you can do overnight, but we will get data, I would have thought within a week as to whether or not the vaccines work or don't," she said.

Jhoots Group, a West Midlands based independent community pharmacy chain, has unveiled plans to expand its digital services after securing a funding worth £8.23m from HSBC bank. The new money will allow the groups branches to offer a digital platform for customers to request prescriptions online, enabling the implementation of a hub and spoke dispensing system to automate prescription deliveries. The innovation aims to reduce the burden of manual processes on pharmacists, allowing staff to use their time efficiently and support the NHS by offering vaccines and minor ailment medicine services. San Jhooty, chief operating officer at Jhoots Group, said: "When faced with the unprecedented challenges of the pandemic, primary and community services came together to support the community and each other.

The University of Lincoln has clinched the top spot on The Guardian's 2024 list for pharmacy and pharmacology studies. This marks a significant advancement from its second-place position in the 2023 rankings, where Ulster University had secured the leading position. Interestingly, Ulster has moved down to claim the second spot this year. Forty universities were assessed using eight criteria, which encompass student satisfaction with teaching, the effectiveness of feedback from instructors, student-to-staff ratio, expenditure per student (excluding academic staff costs), and the average UCAS scores of entrants under 21. Also included were the effectiveness of teaching methods, the proportion of students securing graduate-level employment or pursuing further studies within 15 months of graduation, and the percentage of first-year students progressing into their second year. Among the 40 universities in the ranking list, the University of Lincoln achieved a perfect score of 100 out of 100, followed by Ulster (96.2), Portsmouth (87.9), Leeds (86.3), Glasgow (85.7), Sunderland (84.3), St George's (84.3), Aberdeen (81.3), UCL (81), and Queen's, Belfast (80.1).

The collapse of the three trading entities in the Converse Pharma Group (Testerworld Limited, Doncaster Pharmaceuticals Group Limited and Eclipse Generics Limited) (the Group) in May 2022 undoubtedly caused ripples throughout the pharmacy industry. The Group, a major supplier of pharmaceuticals, had a combined turnover over £300m, employed 1,000 staff members and supplied over 4,000 pharmacies throughout the country. The Group is licensed and regulated by the MHRA. At the beginning of 2021, a breach of the MHRA licensing regulations caused a temporary (but prolonged) cessation of trading. The Group was able to secure the ongoing support of its secured creditors during this time, however, when the licenses were subsequently reinstated, they came with restrictions. Unfortunately for the Group, the period of the suspension and the subsequent restrictions over the licences caused a significant reduction in revenue, from which the Group was unable to recover. Ultimately, by May this year, the companies in the Group had exhausted their working capital and had no prospect of raising the funding they required to continue to trade.

Former chancellor Rishi Sunak on Monday (October 24) won the battle for leader of Britain's Conservative party and will become the country's first prime minister of colour. Penny Mordaunt, the last rival left after Boris Johnson dramatically pulled out, failed to secure the necessary 100 nominations from her fellow MPs. "Rishi Sunak is therefore elected as leader of the Conservative party," senior backbencher Graham Brady said, as Mordaunt pledged her "full support" for Sunak. Sunak's triumph came after Johnson's decision late Sunday to abandon his political comeback bid. Just weeks after he lost out to Liz Truss to lead the ruling Tories, Sunak therefore pulled off a stunning reversal in fortunes. The contest, triggered by outgoing leader Truss's resignation on Thursday, had required candidates to secure the support of at least 100 Conservative MPs by 2:00 pm (1300 GMT) on Monday.

British health agencies have secured funding to develop a standardised approach to test the performance of vaccines being used or in development against monkeypox, days after the World Health Organization labelled the growing outbreak a global health emergency. The Coalition for Epidemic Preparedness Innovations (CEPI) said it would give up to $375,000 to the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Security Agency (UKHSA) to develop standard tools to assess the strength and duration of immune responses generated by current vaccines, and for tests used to detect monkeypox antibody levels. Apart from administration fees, these tools will be made freely available to the global scientific community, paving the way for a common standardised assessment between countries documenting vaccine performance against monkeypox, CEPI said. Until this year, the viral disease has rarely spread outside Africa where it is endemic. But reports of a handful of cases in Britain in early May signalled that the outbreak had moved into Europe. So far, there have been more than 16,000 confirmed cases of monkeypox in more than 75 countries.

The European Commission launched an initiative to deal with the ongoing supply crisis on Tuesday (24 October). The following announcement comes after the shortage of key antibiotics last winter identified by the European Health Emergency Preparedness and Response Authority (HERA) and the European Medicines Agency (EMA). The "European Voluntary Solidarity Mechanism" is a proposed short-term measure that involves a Member State's need for a given medicine to other Member States to redistribute medicines from their available stock. Additionally, the Commission intends to cooperate with member states to improve components of pharmaceutical reform with an aim to strengthen supply security. They are setting up a few actions apart from the launch, a list of critical medicines to analyse the supply chain by early 2024; regulatory flexibilities; strengthening security of supply; and availability of antibiotics and treatments for respiratory viruses by next winter.

The Pharmacists' Defence Association has helped its members to secure around £196,000 last year from employers who treated pharmacists badly or breached their rights in some way. The association strives to help members to resolve workplace disputes quickly, locally, and amicably, however some cases need escalation into the legal system, it said. It helps pharmacists to understand and exercise their rights in case unfair treatment occurs to them. Though no employee expects to be treated badly, this is the reality for some pharmacists, the PDA stated.

The Department of Health in Northern Ireland has acknowledged the efforts of community pharmacies, wholesalers and procurement teams in securing supply of antibiotics for the treatment of Group A Streptococcus infection in Northern Ireland. "Locally community pharmacies, wholesalers and procurement teams have been working tirelessly to secure stock deliveries into Northern Ireland. The Department acknowledges the immense efforts from all involved," it said. "To put this in context, it is estimated that around one month's worth of stock based on normal demand was exhausted in less than 48 hours last week." "While demand is well in excess of what is usual for this time of year, the system has been working hard to replenish stocks as quickly as possible, as such wholesalers are still receiving and making deliveries, with more scheduled over the coming days."

In the pharmaceutical industry, maintaining strict hygiene standards is paramount to ensure the safety and efficacy of products. One of the critical components in achieving this goal is the utilization of sanitary clamps. These clamps play a vital role in securing various connections within pharmaceutical equipment, preventing contamination, and upholding sterile conditions. In this article, we delve into the reasons why sanitary clamps are indispensable for maintaining hygiene in pharmaceutical settings. Contamination Prevention Sanitary clamps serve as a crucial barrier against contamination in pharmaceutical environments. With stringent regulations governing pharmaceutical manufacturing, any compromise in hygiene can result in significant consequences, including product recalls and compromised patient safety. Sanitary clamps are designed to create secure and airtight connections between pipes, hoses, and other components, effectively sealing off potential entry points for contaminants such as bacteria, viruses, and particulate matter. By minimizing the risk of contamination, these clamps help pharmaceutical companies uphold the integrity of their products and adhere to regulatory standards. Moreover, the design of sanitary clamps ensures ease of cleaning and sterilization, further reducing the risk of cross-contamination between batches. Unlike traditional fastening methods that may harbor bacteria or residue, sanitary clamps feature smooth surfaces and minimal crevices, making them easier to sanitize. This not only enhances hygiene but also promotes efficiency in the cleaning process, allowing pharmaceutical manufacturers to maintain high levels of cleanliness without compromising production timelines. Overall, by preventing contamination and facilitating thorough cleaning, sanitary clamps play a crucial role in safeguarding the quality and safety of pharmaceutical products.

The Office for Civil Rights (OCR) at the U.S. Department of Health and Human Services has announced relaxation in HIPAA rules for covered entities and business associates who participate in good faith in the COVID-19 testing site operation. It doesn't stop there, but HIPAA penalties won't apply to covered healthcare providers for practicing telehealth medicine using third-party applications such as Skype or Facebook Messenger

The Office for Civil Rights (OCR) at the U.S. Department of Health and Human Services has announced relaxation in HIPAA rules for covered entities and business associates who participate in good faith in the COVID-19 testing site operation.

To complete the evaluations of Lateral Flow Device (LFD) test kits, the UK Health Security Agency (UKHSA) will approach pharmacies and send 15 combined kits to pharmacies in December. The combined kits will contain a standard LFD pack, one PCR test along with comprehensive instructions. For the evaluation, a part of meeting Medicines and Healthcare products Regulatory Agency (MHRA) obligations, UKSHA needs "dual swabbing through the community pharmacy Covid-19 lateral flow device distribution service." Pharmacies receiving these kits need to finish the current open carton of LFD packs and then open the next standard carton. Pharmacy negotiator PSNC has advised pharmacies to be mindful of "the expiration date of the kit and ensure these are handed out in sufficient time."

People infected with monkeypox can isolate at home if they remain well enough, whilst following measures to limit close contact with others, the UK's health security agency (UKHSA) said on Monday (May 30), part of guidance designed to curb the country's rise in cases of the viral illness. More than 300 suspected and confirmed cases of monkeypox have been reported in May, outside of Africa where the virus is endemic. The usually mild illness spreads through close contact and can cause flu-like symptoms and pus-filled skin lesions. An additional 71 cases of monkeypox have been identified in England, taking the total number of confirmed cases in the UK as a whole to 179 since early May. Scientists are looking into what might explain the unusual surge of cases, given most are not linked to travel. The UKHSA indicated community transmission was occurring in the UK and said infected people should avoid contact with others until their lesions have healed and the scabs have dried off.

The Royal Pharmaceutical Society (RPS) has secured a contract with the National Institute for Health Research (NIHR) to deliver a suite of e-learning modules to help pharmacy professionals "become more research active". The new online resources - due to be launched next summer - are aimed at pharmacists and pharmacy technicians who may not have followed an academic career path or have had little or no experience of research delivery. The e-learning package will allow them to gain new skills so they feel more confident to engage with research and research opportunities. Nine modules are being developed covering how to transform ideas into a research project, find and evaluate evidence and choose the appropriate research methods whilst learning how to apply for research funding and deal with governance issues and publication.